Moving CAR T-cell therapy to earlier treatment lines is crucial. This approach targets cancer before it develops resistance and, more importantly, utilizes patient T-cells that are healthier and more effective, not having been damaged by extensive prior chemotherapy regimens.

The success of early CAR-T cell therapies was partly luck. Future therapies face a high bar, as an ideal target must meet three criteria: 1) be abundant on cancer cells, 2) be indispensable for the cancer's survival, and 3) be dispensable for the patient's healthy tissues to avoid lethal toxicity.

With highly effective treatments like CAR-T and bispecifics moving into earlier lines of therapy for multiple myeloma, the clinical focus must evolve. While efficacy benchmarks have been met, the next advancement requires vigilant attention to safety, particularly infection risks and other side effects of new paradigms.

Five-year follow-up from the CARTITUDE-1 trial suggests a potential cure for multiple myeloma is achievable. With roughly one-third of heavily pretreated patients remaining in remission at five years—and some confirmed as MRD-negative—the concept of a cure is now part of the operational discussion among specialists, a monumental shift for a disease long considered incurable.

Without head-to-head trials, clinicians select between Obicell and Brexacel based on a practical algorithm. Patient factors like age and frailty, disease burden, and logistical concerns like product availability dictate the selection, with safer options prioritized for high-risk patients.

Contrary to typical findings where real-world data underperforms, liso-cel CAR T-cell therapy in CLL demonstrates significantly better outcomes in practice than in its approval trial (over 80% response rate vs. under 50%). This suggests that using the therapy earlier in healthier, less-refractory patients unlocks its true potential.

The next major shift for CAR T-cell therapy is its integration into frontline treatment. Instead of being reserved for relapse, it's being tested as a consolidation therapy that could replace the standard two to three years of maintenance chemotherapy, dramatically shortening treatment duration.

CARTITUDE-IV trial data challenges the idea of reserving CAR-T therapy for high-risk myeloma. In early relapse, standard-risk patients treated with siltacel had a longer progression-free survival than even high-risk patients on the same therapy. This suggests standard-risk patients may gain the most relative benefit from earlier CAR-T intervention compared to standard of care.

The first successful CAR T-cells targeted CD19, a protein on leukemia cells but also on healthy B-cells. The therapy worked because humans can live without B-cells. This "tolerable collateral damage" was serendipitous and highlights the primary challenge for other cancers: finding targets that won't cause fatal damage to healthy organs.